MedTrace Logo

A Study to Assess the Safety and Immunogenicity of the Drug CAT-354 in Healthy Japanese Subjects

NCT01093040 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-08-30

No results posted yet for this study

Summary

To assess the safety of the administration of the drug (CAT-354) in healthy Japanese subjects.

Conditions

  • Healthy

Interventions

DRUG

CAT-354

150 mg CAT-354 or placebo given SC on Day 1

DRUG

CAT-354

300 mg CAT-354 or placebo given SC on Day 1

DRUG

CAT 354

600 mg CAT-354 or placebo given SC on Day 1

Sponsors & Collaborators

  • MedImmune Ltd

    collaborator INDUSTRY

  • AstraZeneca

    collaborator INDUSTRY

  • MedImmune LLC

    lead INDUSTRY

Principal Investigators

  • Katsuro Yagawa, M.D. · Astra Zeneca K.K.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2010-05-31
Completion
2010-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01093040 on ClinicalTrials.gov